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INTRODUCTION 
The severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) is responsible for an ongoing pandemic that 
has already killed over 320,000 people and paralyzed the 
global economy (1). Currently, the main method for labora-
tory diagnosis of SARS-CoV-2 is PCR testing of nasopharyn-
geal swabs. There is an urgent need for highly specific and 
sensitive antibody detection assays to answer fundamental 
questions about the epidemiology and pathogenesis of SARS-
CoV-2 and to implement and evaluate population-level con-
trol programs (2). Efforts to understand the pathogenesis and 
define risk factors for severe SARS-CoV-2 disease have been 
hampered by our inability to identify all infected individuals, 
irrespective of clinical symptoms. To contain the pandemic, 
many countries resorted to the widespread quarantine of cit-
ies and regions. By deploying reliable antibody assays for 
population-level testing, it will be possible to obtain the high-
resolution spatial data needed to implement policies for con-
taining the epidemic and informing strategies for re-opening 
communities and cities. 
Studies with SARS-CoV-2 and other human CoVs demon-
strate that people rarely develop specific antibodies within 
the first 7 days after onset of symptoms (3–7). By 10-11 days 
after onset of symptoms, greater than 90% of SARS-CoV-2 
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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first emerged in late 2019 is 
responsible for a pandemic of severe respiratory illness. People infected with this highly contagious virus 
can present with clinically inapparent, mild, or severe disease. Currently, the virus infection in individuals 
and at the population level is being monitored by PCR testing of symptomatic patients for the presence of 
viral RNA. There is an urgent need for SARS-CoV-2 serologic tests to identify all infected individuals, 
irrespective of clinical symptoms, to conduct surveillance and implement strategies to contain spread. As 
the receptor binding domain (RBD) of the spike protein is poorly conserved between SARS-CoVs and other 
pathogenic human coronaviruses, the RBD represents a promising antigen for detecting CoV-specific 
antibodies in people. Here we use a large panel of human sera (63 SARS-CoV-2 patients and 71 control 
subjects) and hyperimmune sera from animals exposed to zoonotic CoVs to evaluate RBD's performance as 
an antigen for reliable detection of SARS-CoV-2-specific antibodies. By day 9 after the onset of symptoms, 
the recombinant SARS-CoV-2 RBD antigen was highly sensitive (98%) and specific (100%) for antibodies 
induced by SARS-CoVs. We observed a strong correlation between levels of RBD binding antibodies and 
SARS-CoV-2 neutralizing antibodies in patients. Our results, which reveal the early kinetics of SARS-CoV-2 
antibody responses, support using the RBD antigen in serological diagnostic assays and RBD-specific 
antibody levels as a correlate of SARS-CoV-2 neutralizing antibodies in people. 
patients develop specific IgG and IgM (3–6). For SARS-CoV-1 
and the more distantly related MERS-CoV, IgG antibodies 
have been observed to persist for at least one year after infec-
tion (8, 9). These observations strongly support the feasibility 
of using antibody assays for identifying recent and remote 
SARS-CoV-2 infections and for conducting population-level 
surveillance. 
SARS-CoV-2 is a β-coronavirus, a subgroup that includes
the closely related SARS-CoV-1 and the more distantly related 
MERS-CoV and the common-cold human CoVs (HCoV-OC43 
and HCoV-HKU1) (10). Many companies have quickly devel-
oped tests for SARS-CoV-2 antibody detection. These assays 
utilize the inactivated whole virion, viral nucleocapsid pro-
tein or viral spike protein as antigens in ELISA, lateral flow 
or other testing platforms. While the performance of these 
assays has not been fully evaluated, some assays appear quite 
sensitive when used 10 days or more after the onset of symp-
toms (6, 11). The specificity of SARS-CoV-2 antibody assays 
has not been adequately addressed. Humans are frequently 
infected with HCoV-OC43 and HCoV-HKU1 and most adults 
have antibodies to these viruses (10). Any antibody cross-re-
activity between common HCoVs and SARS-CoV-2 would re-
sult in false-positive results interfering with antibody-based 
testing and surveillance for SARS-CoV-2. 
SARS-CoV-1 and HCoV OC43 elicit antibodies that cross-
react against related CoVs (12, 13). Following the SARS-CoV-
1 outbreak in 2003, the overall specificity of serological assays 
utilizing the nucleocapsid protein of SARS-CoV-1 was poor, 
whereas assays based on the spike protein were more specific 
(14–16). In recent studies, the receptor binding domain (RBD) 
of the spike protein of SARS-CoV-2 has shown promise as an 
antigen for specific antibody detection (4, 17, 18). Here we re-
port the production of properly folded recombinant receptor 
binding domains (RBDs) from the spike proteins of SARS and 
common-cold HCoVs in mammalian cells. We use these re-
combinant antigens and a large diverse panel of human and 
animal sera to evaluate the RBD as an antigen for SARS-CoV-
2 serology. We demonstrate that the recombinant SARS-CoV-
2 RBD antigen is highly sensitive and specific for detection of 
antibodies induced by SARS-CoVs. We also observed a strong 
correlation between the levels of RBD-binding antibodies and 
levels of SARS-CoV-2 neutralizing antibodies in patients. Our 
results support the use of RBD-based antibody assays for se-
rology and as a correlate of neutralizing antibody levels in 
symptomatic people who have recovered from SARS-CoV-2 
infections. 
RESULTS 
Expression and characterization of recombinant RBD 
antigens from pathogenic coronaviruses 
The S1 and S2 subunits of the spike (S) protein of Corona-
viruses are required for viral entry. The surface accessible 
receptor binding domain (RBD) on the S1 subunit binds to 
receptors on target cells, whereas the exposure of the fusion 
loop in the S2 subunit induces fusion of the viral envelope to 
the host cellular membranes (19). The RBDs of SARS-CoVs, 
which bind to angiotensin-converting enzyme 2 (ACE2) re-
ceptor on the host cells, are also a major target of human an-
tibodies (Fig. 1A and B). As the RBD is a common target of 
human antibodies and poorly conserved between SARS-CoVs 
and other pathogenic human coronaviruses (Fig. 1C), this do-
main is a promising candidate for use in antibody-based di-
agnostic assays. We expressed the RBD of 2003 and 2019 
SARS-Co-Vs and four common human coronaviruses (HCoV-
HKU-1, -OC43, -NL63 and -229E) as fusion proteins that were 
secreted from human cells. The recombinant RBDs were pu-
rified from the cell culture medium by affinity chromatog-
raphy and purity was confirmed by SDS-PAGE (Fig. 1D). We 
used sera and monoclonal antibodies from animals immun-
ized with SARS-CoV-1 or -2 spike proteins to assess the struc-
tural integrity of the purified recombinant RBD antigens. 
Pooled serum from mice immunized with SARS-CoV-2 spike 
protein had antibodies that bound well to the RBD of SARS-
CoV-2 and poorly to the RBDs of SARS-CoV-1 and other com-
mon HCoVs (Fig. 1E). Sera from mice or rabbits immunized 
with SARS-CoV-1 or cross-reactive monoclonal antibody 240C 
reacted with the RBDs of SARS CoV-1 and -2 but not common 
human CoVs (Fig. 1E). Human serum collected before SARS-
CoV-2 emerged contained antibodies to common α- and β-
HCoVs (NL63 and HKU-1) but not to SARS-CoV RBD antigens 
(Fig. 1E). These results suggest that the purified recombinant 
RBD antigens retain native structures required for specific 
antibody binding. 
Evaluating the specificity of SARS-CoV-2 RBD for serol-
ogy 
To evaluate the specificity of the recombinant SARS-CoV-
2 RBD in serology, we used human sera collected from differ-
ent populations before the current pandemic. The sera were 
tested at a high concentration (1:20 dilution) for binding to 
the recombinant RBDs from SARS-CoV-1, SARS-CoV-2 and 
common α- and β-HCoVs (Fig. 2). Sera collected from healthy
American adults (N = 20) before the SARS-CoV-2 pandemic 
frequently had high levels of antibodies to the recombinant 
RBDs of NL63 and HKU-1 CoVs but not to SARS-CoVs (Fig. 
2A). We also tested archived pre-SARS-CoV-2 pandemic sera 
collected from individuals in South Asia, the Caribbean and 
Central America who had recently recovered from arbovirus 
infections. As in the case of healthy adults from the USA, 
most of the subjects from different parts of the world had 
high levels of antibodies to the RBD of common HCoVs but 
no antibodies to the RBD of SARS-CoVs (Fig. 2B). To assess if 
other human respiratory viruses stimulated antibodies that 
cross-reacted with the recombinant SARS-CoV RBD, we 
tested early convalescent sera from people with laboratory 
confirmed influenza A and respiratory syncytial virus infec-
tions and sera from guinea pigs immunized with a panel of 
different human respiratory viruses (Fig. 2 C and D). Except 
guinea pigs immunized with SARS-CoV-1, none of the sera 
had detectable levels of antibodies to the recombinant RBD 
of SARS-CoVs. 
The known pathogenic human CoVs are members of the 
α-coronavirus and β-coronavirus genera (Fig. 3A). HCoV-
NL63 and 229E are two α-coronaviruses that frequently in-
fect and cause a mild common-cold-like illness in most peo-
ple. HCoV-OC43 and HKU-1 are two group 2A β-
coronaviruses that also commonly infect people and cause 
mild disease. Most adults (>90%) have antibodies to these 
common-cold HCoVs. SARS-CoV-1 and -2 and MERS-CoV are 
group 2B and 2C zoonotic β-coronaviruses that have recently
crossed into humans and caused severe illness. The α- and β-
coronavirus genera also contain a large number of zoonotic 
viruses that infect different animal hosts, which have not 
been implicated in human disease to date. To further assess 
the specificity of SARS-CoV-2 RBD for serology, we obtained 
and tested sera from people who had recently recovered from 
a laboratory-confirmed common-cold HCoV infection and 
sera from guinea pigs immunized with different animal CoVs 
(Fig. 3 B and C). None of the immune sera from people ex-
posed to recent HCoV infections cross-reacted with the re-
combinant RBD of SARS-CoVs. None of the guinea pigs 
vaccinated with different zoonotic CoVs had antibodies that 
cross-reacted with the recombinant SARS-CoV RBDs (Fig. 3B 
and C). These results establish that most individuals, includ-
ing people who have been recently exposed to acute common 
HCoV infections, do not have detectable levels of cross-reac-
tive antibodies to the recombinant RBD of SARS-CoVs. 
Evaluating the sensitivity of SARS-CoV-2 RBD for serol-
ogy 
To evaluate the sensitivity of the RBD of SARS-CoV-2 for 
identifying infected individuals, we obtained a total of 77 se-
rum samples from 63 patients with laboratory-confirmed 
(i.e., PCR positive) SARS-CoV-2 infections collected at differ-
ent times after the onset of symptoms. All the samples were 
tested for binding of total immunoglobulin (Ig) and IgM an-
tibodies to recombinant RBD antigens from SARS-CoVs and 
common-cold HCoVs. The sensitivity of the assay was high 
(98% and 81% respectively for Ig and IgM) for specimens col-
lected 9 days or more after onset of symptoms (Fig. 4A). As 
expected, overall sensitivity was lower (57% and 43% respec-
tively for Ig and IgM) for specimens collected between 7 and 
8 days after onset of symptoms (Fig. 4A). With samples col-
lected 9 days or more after onset of symptoms, we observed 
some Ig and IgM antibody cross reactivity with the RBD of 
SARS-CoV-1 (67% and 30% respectively for Ig and IgM), 
which was anticipated as these viruses are closely related 
group 2B β-coronaviruses (20, 21). When the specimens were
further analyzed to estimate the timing of seroconversion, we 
observed a marked transition from seronegative to seroposi-
tive for both Ig and IgM about 9 days after the onset of symp-
toms (Fig. 4A and B). By day 9 after onset of symptoms, most 
patients had high end-point titers in the RBD Ig ELISA (Fig. 
S1). To analyze the kinetics of all three of the major isotypes 
of serum antibodies within the first 6 weeks after the onset 
of symptoms, we separately measured IgG, IgA, and IgM in 
49 serum samples obtained from SARS-CoV-2 infected pa-
tients at >9 days after onset of symptoms. Most individuals 
(46/49) developed IgG responses (Fig. 4C). IgA and IgM re-
sponses were observed less frequently (IgA = 38/49, IgM 
=34/49) than IgG (Fig. 4C). For 14 individuals with labora-
tory-confirmed SARS-CoV-2 infection, we had two specimens 
collected at different times early in the infection (Fig. 4D). 
Two subjects (P70 and P50) were seronegative within the first 
4 days and seropositive for both Ig and IgM 9 or more days 
after onset (Fig. 4D). For three subjects (P58, P56, P52) the 
acute samples were collected after 9 days and the convales-
cent samples were collected 21 days or more after onset. In 
these individuals both acute and convalescent samples were 
positive, and we observed an increase in Ig and IgM levels in 
the second specimen. For the remaining 9 subjects, the acute 
specimen was collected on day 7 after onset and the conva-
lescent specimen was collected >9 days after onset. Six out of 
the 9 subjects already had specific Ig, IgM or both in the acute 
specimen collected on day 7. All the subjects except one (P54) 
seroconverted or had elevated levels of antibody in the con-
valescent sample collected >9 days after onset of symptoms. 
These results indicate that most people seroconvert between 
days 7 and 9 after onset of symptoms. Subject P54 was an 
outlier and did not develop specific Ig or IgM antibodies. All 
the individuals with documented SARS-CoV-2 had Ig but not 
IgM antibodies that bound to the RBD of common HCoVs, 
which is consistent with their high prevalence in humans 
(Fig. 4A). These results demonstrate that the RBD of SARS-
CoV-2 is a highly sensitive antigen for antibody detection in 
patients 9 days or more after onset of symptoms. 
Antibodies to the RBD of SARS-CoV-2 as a correlate of 
neutralizing antibody response 
The administration of convalescent plasma containing an-
tibodies to SARS-CoV-2 is being evaluated for patients with 
severe disease. While the FDA has not approved convalescent 
plasma therapy, on May 1, 2020, the FDA recommended that 
SARS-CoV-2 neutralizing titers of at least 1:160 should be 
used for human passive immunization studies. Further, the 
FDA also recommended that a titer of 1:80 may be acceptable 
if an alternative matched unit is not available. As the RBD 
domain of S protein is critical for viral entry, antibodies tar-
geting this domain of SARS-CoV-2 are likely to be neutraliz-
ing and potentially protective, as is seen in cell culture and 
animal models for other pathogenic CoVs (19, 22). To assess 
the relationship between the RBD-binding activity and the 
neutralizing antibody response, we tested 50 PCR-confirmed 
SARS-COV-2 patient immune sera in a SARS-CoV-2 luciferase 
neutralization assay (Fig. 5). As judged by the Spearman test 
(ρ = 0.86, P < 0.0001), we observed that the magnitude of the
total RBD-binding Ig antibody strongly correlated with the 
levels of neutralizing antibodies in SARS-CoV-2 patients (Fig. 
5A). Moreover, the patient samples with high levels of IgM 
antibodies were strongly associated with the highest neutral-
izing antibody titers in early convalescence (Spearman ρ =
0.83, P < 0.0001; Fig. 5B, <6 weeks after onset of symptoms). 
The neutralizing antibody kinetics in patients mirrored the 
kinetics of RBD antibody development (Fig. 5C and Fig. S2). 
None of the patients with confirmed SARS-CoV-2 infection 
(0/8) had any detectable levels of neutralizing antibodies 
within the first eight days after the onset of symptoms. While 
low levels of neutralizing antibody titers were detectable in 
91% of patients (20/22) 21 days after the onset of symptoms, 
only 73% of patients (16/22) had a neutralization titer of at 
least 1:80. 
Currently, patients who have had a documented SARS-
CoV-2 infection identified by RT-PCR or a serologic test, and 
who are clear of symptoms for at least 14 days, are recruited 
for convalescent plasma donation. We evaluated the neutral-
izing potency in patient samples collected between 1 and 40 
days with a titer of at least 1:160 (Fig. 5D). We observed that 
32% of patients (7/22) developed weak to no neutralizing an-
tibodies even 21 days after onset of symptoms, suggesting 
that days after the start of symptoms is a poor determinant 
of the levels of SARS-CoV-2 neutralizing antibodies in the pa-
tients included in our study, particularly within the early con-
valescent phase (<6 weeks). To evaluate whether a simple 
RBD ELISA can be used as a surrogate for neutralizing po-
tency in SARS-COV-2 patients, we analyzed the relationship 
between the level of total Ig antibody to RBD and a neutral-
izing antibody titer of at least 1:160. We observed that 22/24 
people who had a substantial total Ig binding antibody to 
RBD (>1.5 OD) also developed a robust neutralizing antibody 
titer (Fig. 5E). Notably, only 3/26 people who developed a rel-
atively weak RBD-binding antibody had a neutralizing anti-
body titer higher than 1:160. One subject (P54) neither 
seroconverted for RBD antigen nor developed neutralizing 
antibodies to SARS-CoV-2 (Fig. 4D and E, and Fig. S2). 
DISCUSSION 
Serology is critical to understanding the transmission, 
pathogenesis, mortality rate and epidemiology of emerging 
viruses. In the few months after the discovery of SARS-CoV-2 
as a human pathogen, scientists have developed a large num-
ber of antibody assays and many commercial tests are now 
available. Although none of the assays have been fully vali-
dated yet, the FDA has granted emergency use authorization 
(EUA) for multiple tests, while stressing the need for further 
validation. Investigators have already encountered problems 
with the specificity and sensitivity of commercial assays 
rushed to market (4, 22). Widespread use of inaccurate anti-
body assays could lead to policies that exacerbate the current 
SARS-CoV-2 pandemic instead of containing it. 
To address the need for reliable antibody-based diagnostic 
assays, we focused on the RBD domain of the spike protein 
because this region is poorly conserved between different 
CoVs and is also known to be a major target of human anti-
bodies (19). A major concern with using a protein domain in-
stead of a full-length protein or whole virion for antibody 
detection is possible reduction in assay sensitivity. However, 
we observed that over 95% of SARS-CoV-2 patients developed 
antibodies to the RBD 9 days after onset of symptoms. Alt-
hough our study included only a few recent convalescent sera 
and relatively large numbers of presumably positive samples 
from past common human CoV infections, the high specific-
ity of the RBD antigen was also evident with the serum spec-
imens from animals that were hyperimmunized with other 
zoonotic CoVs. Some patients infected with SARS-CoV-2 had 
antibodies that cross-reacted with the RBD of SARS-CoV-1. 
We have not tested the more distantly related RBD Ag from 
MERS CoV or the serum samples from individuals with con-
firmed MERS infection. Since SARS-CoV-1 and MERS CoV se-
roprevalence are very low in humans, the SARS-CoV-2 
antibody cross-reactivity with SARS-CoV-1 is unlikely to pose 
diagnostic challenges. Other recent studies that have been 
published or under peer review also support the high speci-
ficity and sensitivity of the SARS-CoV-2 RBD for antibody de-
tection (4, 17, 18). Amanat and colleagues tested samples from 
SARS-CoV-2 patients collected at the beginning of the epi-
demic in the USA and reported that the full length S protein 
and the RBD performed well for specific antibody detection 
(17). Okba and colleagues compared the performance of dif-
ferent SARS-CoV-2 antigens for antibody detection using 
samples from 10 SARS-CoV-2 patients in Europe (4). For the 
SARS-CoV-2 spike RBD, they observed levels of specificity 
and sensitivity that were comparable to our results reported 
here. The S2 subunit, which comprises conserved regions be-
tween CoVs, was less specific than the RBD (4). Perera and 
colleagues evaluated the performance of the RBD for anti-
body detection using samples from 24 SARS-CoV-2 patients 
in Hong Kong (18). They also observed high specificity and 
sensitivity when patients were tested 10 days or more after 
onset of illness. Our study with 77 specimens from 63 docu-
mented SARS-CoV-2 patients, which includes patients pre-
senting to hospitals in North Carolina and Georgia with 
varying levels of severity, together with these recent studies 
conducted in New York, Europe and Hong Kong, strongly 
support the use of SARS-CoV-2 RBD as an antigen for anti-
body detection. 
We designed the assay for separate detection of RBD-
specific total Ig and IgM. As the pandemic is ongoing and 
most infections are likely to have occurred within the past 
few months, infected individuals have variable levels of anti-
gen-specific IgG, IgM and IgA (Fig. 4C). To maximize assay 
sensitivity and to prevent different antibody isotypes compet-
ing for binding sites and reducing assay signal, we measured 
total Ig. We did not observe any decrease in assay specificity 
by designing the assay to monitor levels of total Ig instead of 
IgG binding to the RBD even at high serum concentration or 
with hyperimmune sera. Our study showed that IgM and IgA 
antibodies can also be detected using RBD-based serological 
assays. Both IgA and IgM antibodies are relatively short lived 
and indicative of a recent exposure. When conducting large 
scale population level surveillance for SARS-CoV-2 antibod-
ies, it will be possible to distinguish recent from remote in-
fections by measuring both total Ig and IgM (or IgA) binding 
to the RBD. 
Antibody assays that correlate with protective immune re-
sponses in individuals who have recovered from SARS-CoV-2 
infection and also reflect herd immunity at a population level 
are urgently needed to define each individual’s risk of disease 
and to identify communities at high risk for new waves of 
infection. In animal studies with SARS-CoV-1, virus-neutral-
izing antibodies were strongly correlated with protective im-
mune responses (19). We observed a striking correlation 
between the levels of RBD antibodies in patients and the abil-
ity of patient sera to neutralize SARS-CoV-2 virus. Other 
groups have recently reported finding a strong correlation be-
tween spike/RBD antibodies and SARS-CoV-2 neutralization 
in patients infected with SARS-CoV-2 (4, 17, 18). Our results 
point out that roughly one-third of patients develop very low 
or no neutralizing antibodies to SARS-CoV-2 and that Ig and 
IgM antibodies are useful predictors of neutralizing antibody 
levels in patients in the early convalescent phase (<6 weeks). 
As people developing a high level of RBD-binding antibodies 
(>1.5 OD) also have a robust neutralizing response, a simple 
RBD-based ELISA can be a useful tool to identify blood 
plasma donors. While further studies are needed to fully eval-
uate RBD antibodies as correlate of protective immunity, the 
results to date indicate that RBD antibodies are a promising 
correlate of protection in the early convalescent phase. A sim-
ple antibody detection assay that also predicts individual-
level risk of disease will be a major advance for vaccine de-
velopment and immunogenicity of vaccines because SARS-
CoV-2 neutralization assays are time-consuming and require 
BSL-3 containment. 
One SARS-CoV-2 patient (P54) who tested positive for vi-
ral RNA and required hospitalization did not develop RBD-
specific Ig, IgM or neutralizing antibodies, even at 16 days 
after the onset of symptoms. This was the only person among 
the 68 PCR positive subjects who did not seroconvert by 9 
days after onset of symptoms in the RBD-based assay. While 
we cannot rule out the possibility of a false positive PCR test 
result, others have also reported rare instances where people 
infected with SARS-CoVs have atypical, dampened immune 
responses (23). Further studies are needed to establish the 
frequency and significance of atypical antibody responses in 
SARS-CoV-2 patients and characterize the serological reper-
toire and epitopes targeted by the antibodies in convalescent 
sera. 
As SARS-CoV-2 infections in the southeastern U.S. have 
started to increase relatively recently, all convalescent sam-
ples used in this study were collected within 90 days follow-
ing onset of symptoms. In most patients, the convalescent 
sera had high end-point titers (>1:1000) in the RBD Ig ELISA 
supporting the utility of this assay even as antibody levels 
start to wane over time. We need to prioritize studies to pro-
spectively monitor SARS-CoV-2 patients to determine the 
long-term kinetics of antibody levels and the performance of 
antibody detection assays over time. 
All the SARS-CoV-2 human immune sera used for this 
study were collected from symptomatic patients that in-
cluded many with serious illness requiring hospitalization. 
The research community currently does not know if individ-
uals experiencing mild/inapparent symptoms after SARS-
CoV-2 infection have similar kinetics and levels of RBD-
binding antibodies as those experiencing symptomatic infec-
tions. Studies must be done with individuals experiencing 
mild/inapparent SARS-CoV-2 infections to define the kinetics 
and levels of RBD antibodies before implementing large pop-
ulation-level antibody testing. 
MATERIALS AND METHODS 
Study design 
The goal of the study was to evaluate the performance of 
RBD-based spike antigen for reliable detection of SARS-CoV-
2-specific antibodies. We produced properly folded RBD from
the spike proteins of SARS and common-cold HCoVs in mam-
malian cells and used this antigen to evaluate a large panel
of human sera from documented SARS-CoV-2 patients and
control subjects, and hyperimmune sera from animals ex-
posed to zoonotic CoVs. We also used a SARS-CoV-2 lucifer-
ase neutralization assay to assess the dynamics of the
neutralizing antibody response and its association with the
RBD-binding activity.
Structural analysis
The structure coordinate sets of the spike proteins, spike 
protein complexes with their cognate receptor ACE2 and 
monoclonal antibodies were obtained from the Protein Data 
Bank (PDB). The structures were aligned to the reference 
spike protein using the PyMOL Molecular Graphics System 
(Version 1.2r3pre, Schrödinger, LLC). Molecular figures were 
drawn using PyMol. The PDB coordinates used for the 
structural alignments and analysis were as follows: SARS-
CoV-2 spike (6VSB), SARS-CoV-1 spike (6CRV), SARS-CoV-1 
spike/S230 (6NB6), SARS-Co-V1 spike RBD/80R (2GHW), 
SARS-CoV-1 spike RBD/ m396 (2DD8), SARS-CoV-1 spike 
RBD/F26G19 (3BGF), SARS-CoV-2 spike RBD/CR3022 
(6W41). 
Protein expression and purification 
We used the following structure coordinates of the coro-
navirus spike proteins from the PDB to define the boundaries 
for the design of RBD expression constructs: SARS-CoV-2 
(6VSB), SARS-CoV-1 (6CRV), HKU-1 (5I08), OC43 (6NZK), 
229E (6U7H) NL63 (6SZS). Accordingly, a codon-optimized 
gene encoding for S1-RBD [SARS-CoV-1 (318 – 514 aa, 
P59594), SARS-CoV-2 (331 – 528 aa, QIS60558.1), OC43 (329 
– 613 aa, P36334.1), HKU-1 (310 – 611 aa, Q0ZME7.1), 229E
(295 – 433 aa, P15423.1) and NL63 (480 – 617 aa, Q6Q1S2.1)]
containing human serum albumin secretion signal sequence,
three purification tags (6xHistidine tag, Halo tag, and Twin-
Strep tag) and two TEV protease cleavage sites was cloned
into the mammalian expression vector pαH. S1 RBDs were
expressed in Expi293 cells (ThermoFisher) and purified from 
the culture supernatant by nickel-nitrilotriacetic acid agarose 
(Qiagen). 
Generation of SARS-CoV-2 Spike VRP and immunized 
mouse sera 
To generate virus replicon particles (VRPs), the SARS-
CoV-2 S gene was inserted into pVR21 3526 as previously de-
scribed (24). In summary, the SARS-CoV-2 S gene was ligated 
into pVR21 following digestion by restriction endonuclease 
sites, PacI and ApaI. T7 RNA transcripts were generated us-
ing the SARS-CoV-2-S-pVR21 construct in conjunction with 
plasmids containing the Venezuelan equine encephalitis vi-
rus envelope glycoproteins and capsid protein. The RNA tran-
scripts were then electroporated into baby hamster kidney 
fibroblasts and monitored for cytopathic effect. VRP were 
harvested 48 hours after electroporation and purified via 
high-speed ultra-centrifugation. To generate serum samples 
against SARS-CoV-2, 10-week-old BALB/c mice (Jackson 
Labs) were inoculated via footpad injection with the VRP and 
boosted with the same dose one time three weeks later. Se-
rum samples were then collected from individual animals at 
2 weeks post-boost and pooled for use in assays. 
Human specimens 
All human specimens used in these studies were obtained 
after informed consent under good clinical research practices 
(GCP) and compliant with oversight by the relevant institu-
tional review boards (IRBs). A list of the SARS-CoV-2 patient 
samples included in the study with basic demographic and 
clinical information can be found in Table S1. 
UNC Hospital Specimens: Sera for this study were rem-
nants from samples submitted to the UNC Hospital McLen-
don Clinical Laboratories or Blood Bank. SARS-CoV-2 patient 
samples were obtained from patients with positive RT-PCR 
test result (in-house assay developed and validated by UNC 
Hospital McLendon Clinical Laboratory) for SARS-CoV-2. 
SARS-CoV-2 negative samples were obtained from patients 
with other diagnoses or from samples collected prior to De-
cember 2019 and cryopreserved at -80°C. 
Emory University School of Medicine Specimens: Speci-
mens were obtained from patients with symptomatic illness 
and clinical testing confirming SARS-CoV-2 by PCR (CDC 
SARS-CoV-2 test). De-identified specimens were shared with 
researchers at UNC consistent with local IRB protocols 
(Emory IRB# 00110683 and 00022371). 
Blood plasma donor study: Convalescent sera was ob-
tained from donors who volunteered for plasma collections 
at the UNC Donation Center. Fresh sera collected as part of 
the standard plasmapheresis procedure were saved for re-
search from donors who signed informed consent. UNC IRB 
20-1141 is conducted under good clinical research practices
(GCP) and is compliant with institutional IRB oversight. All
donors had confirmed SARS-CoV-2 infection by nasopharyn-
geal swab indicating the presence of SARS-CoV-2 RNA as per-
formed by EUA approved qRT-PCR in a US laboratory with a
Clinical Laboratory Improvement Amendments (CLIA) certi-
fication. All donors had recovered from their SARS-CoV-2 ill-
ness and were at least 14 days post last symptoms. Donors
who presented for plasma collection prior to 28 days from
their last symptoms had a confirmed negative nasopharyn-
geal RT-PCR test done within 72 hours prior to donation.
Healthy Unexposed Donors: Samples from healthy U.S. 
adult donors were obtained by the La Jolla Institute for Im-
munology (LJI) Clinical Core or provided by a commercial 
vendor (Carter Blood Care) for prior, unrelated studies be-
tween early 2015 and early 2018, at least one year before the 
emergence of SARS-CoV-2. The LJI Institutional Review 
Board approved the collection of these samples (LJI; VD-112). 
Samples from the Caribbean, Central America and South Asia 
were obtained from archived samples at UNC collected before 
December 2019 for other studies. 
Human and Animal Specimens from BEI Resources: The 
following reagents were obtained through BEI Resources, 
NIAID, NIH as part of the Human Microbiome Project: 
Pooled sera obtained from rabbits dosed with a recombinant 
SARS-CoV spike protein (NRC-772), monoclonal anti-SARS-
CoV S protein (Similar to 240C) (NR-616), anti-porcine res-
piratory coronavirus (PRCoV; ISU-1) serum obtained from 
Pig (NR-460), anti-porcine Transmissible Gastroenteritis Vi-
rus obtained from pig (NR-458), anti-porcine respiratory 
coronavirus (PRCoV; ISU-1) serum obtained from guinea pig 
(NR-459), Anti-SARS Coronavirus obtained from guinea pig 
(NR-10361), Anti-Bovine Coronavirus (mebus) obtained from 
guinea pig (NR-455), Anti-Feline Infectious Peritonitis Virus, 
79-1146 obtained from guinea pig (NR-2518), Anti-Avian
Infectious Bronchitis Virus, Massachusetts obtained from 
guinea pig (NR-2515), Anti-Turkey Coronavirus, Indiana ob-
tained from guinea pig (NR-9465), Anti-Canine Coronavirus, 
UCD1 obtained from guinea pig (NR-2727), Anti-Human 
Parainfluenza Virus 2 obtained from guinea pig (NR-3231), 
Anti-Simian Virus 5 obtained from guinea pig (NR-3232), 
Anti-Human Parainfluenza Virus 3 obtained from guinea pig 
(NR-3235), Anti-Bovine Parainfluenza Virus 3 obtained from 
guinea pig (NR-3236), Anti-Human Parainfluenza Virus 4A 
obtained from guinea pig (NR-3239), Anti-Human Parainflu-
enza Virus 4B obtained from guinea pig (NR-3240), Human 
Convalescent Serum 001 to 2009 H1N1 Influenza A Virus 
(NR-18964), Human Convalescent Serum 002 to 2009 H1N1 
Influenza A Virus (NR-18965), and Human Reference Antise-
rum to Respiratory Syncytial Virus (NR-4020). For some ani-
mal CoV anti-serum samples, the certificate of analysis 
provided by the BEI Resources confirmed the presence of 
neutralizing and binding antibodies (see Table S1). 
In-house RBD Ig and IgM ELISA 
All serum specimens tested by ELISA assay were heat-in-
activated at 56°C for 30 min to reduce risk from any possible 
residual virus in serum. Briefly, 50 μl of spike RBD antigen at
4 μg/ml in Tris Buffered Saline (TBS) pH 7.4 was coated in
the 96-well high-binding microtiter plate (Greiner Bio-One 
cat # 655061) for 1 hour at 37°C. Then the plate was washed 
three times with 200 μl of wash buffer (TBS containing 0.2%
Tween 20) and blocked with 100 μl of blocking solution (3%
milk in TBS containing 0.05% Tween 20) for 1 hour at 37°C. 
The blocking solution was removed, and 50 μl of serum sam-
ple at 1:20 or indicated dilutions in blocking buffer was added 
for 1 hour at 37°C. The plate was washed in the wash buffer, 
50 μl of alkaline phosphatase-conjugated secondary goat
anti-human secondary antibody at 1:2500 dilution was added 
for 1 hour at 37°C. For measuring total Ig, a mixture of anti-
IgG (Sigma Cat # A9544), anti-IgA (Abcam Cat # AB97212), 
and anti-IgM (Sigma Cat # A3437] were added together. For 
measuring specific antibody isotype, only secondary goat 
anti-human IgG or IgA or IgM was used. The plate was 
washed, and 50 μl p-Nitrophenyl phosphate substrate
(SIGMA FAST, Cat No N2770) was added to the plate and ab-
sorbance measured at 405nm using a plate reader (Biotek 
Epoh, Model # 3296573). For testing animal sera, the second-
ary antibody was matched to the species as follows: goat anti-
mouse IgG (Sigma, A3688), goat anti-rabbit IgG (Abcam, 
ab6722), goat anti-pig IgG (Abcam, ab6916), and goat anti-
guinea pig IgG (Abcam, ab7140). 
SARS-CoV-2-Washington neutralization assays 
Full-length viruses expressing luciferase were designed 
and recovered via reverse genetics and described previously 
(25, 26). Viruses were tittered in Vero E6 USAMRID cells to 
obtain a relative light units (RLU) signal of at least 20X the 
cell only control background. Vero E6 USAMRID cells were 
plated at 20,000 cells per well the day prior in clear bottom 
black-walled 96-well plates (Corning 3904). Neutralizing an-
tibody serum samples were tested at a starting dilution of 
1:20, and were serially diluted 4-fold up to eight dilution 
spots. Antibody-virus complexes were incubated at 37°C with 
5% CO2 for 1 hour. Following incubation, growth media was 
removed and virus-antibody dilution complexes were added 
to the cells in duplicate. Virus-only controls and cell-only con-
trols were included in each neutralization assay plate. Fol-
lowing infection, plates were incubated at 37°C with 5% CO2 
for 48 hours. After the 48 hour incubation, cells were lysed 
and luciferase activity was measured via Nano-Glo Luciferase 
Assay System (Promega) according to the manufacturer’s 
specifications. SARS-CoV-2 neutralization titers were defined 
as the sample dilution at which a 50% reduction in RLU was 
observed relative to the average of the virus control wells. 
Statistical analysis 
Each data points in Fig. 1E, Fig. 2, Fig. 3B and 3C, Fig. 4 
and 5 are presented as means of technical duplicates. The cor-
relation of RBD binding and neutralization titers shown in 
Fig. 5A and Fig. 5B was evaluated using a Spearman correla-
tion coefficient (rs) and the associated two-tailed p-value 
(GraphPad Prism, version 8). Receiver operating characteris-
tic (ROC) analyses were performed to establish cutoff values 
for SARS-CoV-2 seropositivity using SPSS software. Statistical 
analyses were performed using SPSS software ver. 26.0 (IBM, 
Armonk, NY, USA). 
SUPPLEMENTARY MATERIALS 
immunology.sciencemag.org/cgi/content/full/5/48/eabc8413/DC1 
Fig. S1. Titration curves of sera from SARS-CoV-2 positive patients. 
Fig. S2. Seroconversion of SARS-CoV-2 neutralizing antibodies. 
Fig. S3. Estimation of RBD ELISA assay cutoff. 
Table S1. Summary of samples tested and associated characteristics (Excel spread-
sheet). 
Table S2. Raw data file (Excel spreadsheet). 
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Fig. 1. Production and 
characterization of the 
RBD of the coronavirus 
spike antigens. (A) The 
spike protein on the 
virion surface engages its 
cognate receptor via the 
RBD. (B) RBD of the 
spike protein is the main 
human antibody target in 
SARS-CoV-1. (C) The 
amino acid sequence 
corresponding to RBD of 






PAGE of purified spike 
RBD antigens from 
different CoVs. (E) 
Binding characterization 
of the spike RBD antigens 
with immune sera and a 
monoclonal antibody. 
SARS-CoV-1 monoclonal 
antibody (240C), serum 
from a mouse immunized 
with VRP expressing 
SARS-CoV-2 or SARS-
CoV-1 spike protein, 
serum from a rabbit 
immunized with SARS-
CoV-1 spike protein and 
an archived human 
sample collected before 
SARS-COV-2 were tested 
for binding against RBD 
spike antigens from 
SARS-CoV-2, SARS-Co-
V-1, HCoVα (NL63) and
HCoVβ (HKU-1).
 
Fig. 2. Evaluation of SARS-CoV-2 spike RBD antigen specificity using blood samples collected before the 
emergence of SARS-COV-2. Spike RBD antigen binding was assessed by in-house ELISA assay against a panel of 
de-identified archived serum specimens obtained from (A) American healthy adults; (B) Convalescent sera from 
dengue/Zika patients in South Asia, Caribbean, and Central America; (C) People who had recently recovered from 
viral respiratory illnesses; and (D) Guinea pigs immunized with respiratory viruses or SARS-CoV-1 spike protein. 
The cutoff values determined by the receiver operating (ROC) curve analysis (Fig S3) for the ELISA assay are 
indicated by the broken line. 
Fig. 3. Evaluation of 
SARS-CoV-2 spike RBD 
antigen specificity 
against common human 
CoVs and animal CoVs 
sera. (A) Phylogenic tree 
of the spike protein from 
representative 
coronaviruses. 
Coronavirus genera are 
grouped by classic 
subgroup designations (α, 
βa-d, γ, and δ). SADS-CoV
is a distinctive member of 
the α subgroup (indicated
by *). Numbers following 
the underscores in each 
sequence correspond to 
the GenBank accession 
number. Spike RBD 
antigen binding was 
assessed by in-house 
ELISA assay using (B) 
human convalescent 
samples obtained from 
PCR-confirmed HCoVα
(NL63, black) and HCoVβ
(OC43 (red), HKU-1 
(blue)) infections and (C) 
sera from guinea pigs or 
pigs immunized with spike 
antigen from SARS-CoV-1 
or indicated animal CoV. 
The cutoff values for the 
ELISA assay are indicated 
by the broken line. Feline 
Infectious Peritonitis 
Virus, 79-1146 (Feline CoV, 
Pink); respiratory 
coronavirus strain ISU-
1(Porcine CoV, green); 
Porcine  Transmissible 
Gastroenteritis Virus (TGEV, orange); Bovine Coronavirus strain mebus (Bovine CoV, cyan); Avian Infectious 
Bronchitis Virus, Massachusetts (Avian CoV, violet); Turkey Coronavirus, Indiana (Turkey CoV, yellow); Canine 
Coronavirus strain UCD1 (Canine CoV, hot pink); SARS-CoV-2 (SARS, brown). 
Fig. 4. Evaluation of SARS-
CoV-2 spike RBD antigen 
sensitivity. (A) Overall SARS-
CoV-2 spike RBD antigen 
sensitivity as assessed by the 
in-house Ig and IgM ELISA 
assays using clinical 
specimens obtained from 
PCR-confirmed SARS-CoV-2 
subjects. For comparison, 
binding results of the RBD 
spike antigens from a 
representative HCoVβ (HKU-
1) with the same specimens 
are also presented. The 
changes of the levels of (B) 
total Ig and (C) IgG, IgA and 
IgM antibodies binding to RBD 
of the SARS-CoV-2 spike 
antigen. The binding of the 
spike RBD antigen from SARS-
CoV-2 to 49 de-identified 
serum samples obtained from 
SARS-CoV-2 positive subjects 
at different time points since 
onset of symptoms are 
presented. The cutoff values 
for the ELISA assay are 
indicated by the broken line. 
The dashed blue box in (B) 
indicates a single PCR positive 
and seronegative subject. 
Seroconversion of (D) total Ig 
and (E) IgM antibodies against 
RBD of the SARS-CoV-2 spike 
antigen among 14 
representative SARS-CoV-2 
patients during the acute 
phase since onset of 
symptoms. The first sample 
(green) and follow-up sample 
(red) are connected by black 
arrow. The time interval 
between the first and follow-
up sample are provided on the 
x-axis. The binding signals 
below the broken line are 
denoted as seronegative.
Fig. 5. Correlation between spike RBD antigen binding and SARS-CoV-2 neutralizing antibody titers. 
Correlations between (A) total Ig and (B) IgM RBD binding and the SARS-CoV-2 neutralizing antibody titers. 
Scatter plots were generated using individual serum binding to RBD antigen (y-axis) versus SARS-CoV-2 
neutralizing antibody titers (x-axis). The nonparametric Spearman correlation coefficient (rs) and the 
associated two-tailed p-value were calculated (GraphPad Prism, version 5.0). (C) Relationship between SARS-
CoV-2 neutralizing antibody titer and days after onset of symptoms. (D) Total Ig antibody binding to RBD as a 
surrogate for identifying people with high SARS-CoV-2 neutralizing antibodies. A total of 50 serum samples 
collected between 1 and 39 days after onset of symptoms from PCR-confirmed SARS-CoV-2 subjects were 
measured for Ig and IgM binding to spike RBD antigen and SARS-CoV-2 neutralization assay. The FDA-
recommended neutralizing antibody titer for plasma therapy (1:160) is indicated by the broken green line. 
